Livzon Pharmaceutical Group's (HKG:1513, SHE:000513) net profit attributable to shareholders rose 5.5% to 2.06 billion yuan from 1.95 billion yuan a year earlier, according to a Hong Kong Stock Exchange disclosure on Wednesday.
Earnings per share rose 6.7% year on year to 2.24 yuan from 2.10 yuan.
The Chinese pharmaceutical company's operating income fell 5% to 11.8 billion yuan from 12.4 billion yuan in the preceding year, the disclosure said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.